INTRODUCTION

Glioblastoma is the most aggressive and most common malignant brain tumour that affects adults. The mean age at diagnosis is around 65 years old and the incidence rate is 3.23 cases per 100,000. The average life expectancy is 10–15 months and the estimated 2-year survival rate is 8%–25%. Glioblastoma affects many aspects of a person’s life and causes a variety of progressive, and usually concurrent, symptoms such as headache, hemiparesis, cognitive problems, personality changes and communication problems. The complexity of symptoms and problems can have a negative impact on the health-related quality of life (HRQoL)—not only that of patients, but also relatives.
patients with glioblastoma are a vulnerable group, with more severe symptoms of depression and illness disturbance compared to patients with other malignant diseases. As such, they experience low HRQoL prior to surgery, early after surgery and two months after surgery. A low HRQoL score early after surgery is a known negative prognostic factor for survival. Relatives of patients with glioblastoma report distress pre-surgery and at the 2-month follow-up. In a previous study, we reported that relatives of patients with glioblastoma have worse mental HRQoL and more frequent symptoms of anxiety and depression prior to surgery than the patients. Apart from studies on patients with malignant glioma (with WHO grade III and IV grouped together), longitudinal descriptions and comparisons of patients with glioblastoma and their relatives in the literature are sparse. The few longitudinal studies of HRQoL focussing on both patients and relatives usually do not exceed six months post-surgery, even though six-month survival in this patient group is estimated at 60%–65% and 8%–25% in the case of two-year survival. Thus, there is a lack of data on how HRQoL and psychological symptoms in patients with glioblastoma change—compared to their relatives—over the entire course of disease. The aim of this study was to describe and compare (a) HRQoL and psychological symptoms between patients with glioblastoma and their relatives, and (b) HRQoL between patients and a control sample from the general population over time.

2 | METHODS

2.1 | Design and participants

This study was designed as a prospective longitudinal cohort study. Inclusion criteria were established as: patients aged 18 years old or over, with radiologically verified glioblastoma, identified in a population-based study at the University Hospital in Gothenburg, Sweden. Glioblastoma was defined according to the 2016 WHO classification as described in our previous study. The majority of tumours (>80%) in the cohort were IDH-wildtype. Exclusion criteria were emergency surgery, operated at another hospital, non-conversant in Swedish, reoperation, other histological diagnosis after surgery and patients without a relative. For recruitment of relatives, the patients were asked to select the person closest to them, aged 18 years old or over, regardless of whether they were living together or not. At baseline, the paired participants comprised 63 patients and 63 relatives. Further description and a flow chart of the enrolment process, as well as baseline demographic data of the study cohort, have been presented in our earlier study.

2.2 | Questionnaires

2.2.1 | Health-related quality of life assessment

To measure and compare patients’ and relatives’ subjective experience of HRQoL over time, the generic Short Form Health Survey (SF-36) questionnaire was chosen as a validated instrument. SF-36 is divided into eight multi-item scales: physical functioning (PF), role limitations due to physical problems (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE) and mental health (MH). The raw scores from the eight multi-item scales are converted via a specific algorithm to a 0–100 grade, where higher scores represent better health state. The items in SF-36 can be summarized by two general health indices, Physical Component Summary (PCS) and Mental Component Summary (MCS), covering the main dimensions of physical health and mental health. An age- and gender-matched samples for each patient who participated in the study were manually retrieved from the SF-36 general population data. This was done at every measured timepoint.

2.2.2 | Psychological symptoms assessment

To evaluate and compare patients’ and relatives’ psychological symptoms over time, the Hospital Anxiety and Depression scale (HADS) was used. HADS is a validated generic measuring instrument that assesses

| Table 1 Patients demographic data, molecular tumour characteristics and post-surgery treatment (n = 63). |
|----------------|--------|
| Patients | n (%) |
| Total sample | 63 |
| Male/Female | 40(63)/23(37) |
| md (range) | |
| Age (in years) at surgery | 62 (37–77) |
| Localization of tumour | |
| Unilateral | 44 (69.8%) |
| Bilateral | 2 (3.2%) |
| Central | 17 (27.0%) |
| Operation side | |
| Right | 32 (50.8%) |
| Left | 25 (39.7%) |
| Bilateral | 6 (9.5%) |
| Comorbidity | |
| Yes | 33 (52.4%) |
| No | 28 (44.4%) |
| Unknown | 2 (3.2%) |
| Molecular tumour characteristics | |
| MGMT promoter methylation | 46% |
| IDH-gene mutation | 6% |
| Post-surgery treatment | |
| Primary oncological treatment | 83% |
| Radiotherapy and chemotherapy | 51% |
| Radiotherapy | 13% |
two main areas, symptoms of anxiety (HADa) and depression (HADd). Each main area is divided into seven questions, each scored 0–3, resulting in a total range of 0–21 for each main area. Scores <8 indicate the probable absence of clinically meaningful degrees of anxiety or depression, scores ≥8 indicate the possible presence of clinically meaningful degrees of depression or anxiety, and scores ≥11 indicate the probable presence of clinically meaningful degrees of depression or anxiety.19,20

2.3 Data collection

Data was collected between 2012 and 2018. Patients and their relatives completed the self-reported questionnaires pre-surgery, 3 weeks post-surgery (when patients received radiation), 12 weeks post-surgery (when receiving chemotherapy) and then every 6 months until 2 years post-surgery. At baseline, a research assistant distributed the questionnaires to the participants. At the follow-ups, questionnaires were sent to the participants by mail. Demographic data, molecular tumour characteristics and post-surgery treatment were collected from patients’ electronic medical records and are presented in Table 1).

2.4 Statistics

Descriptive statistics were presented as means, standard deviation (SD), percentages and 95% confidence intervals (CI) at every time point. Descriptive data are presented until 2 years post-surgery and comparative data were analysed until eighteen months post-surgery due to the small sample size at the 2-year time point. Wilcoxon signed-rank test was used to evaluate the difference between patients and their relatives and between patients and the age-and gender-matched sample. A p-value ≤.05 (two sided) was considered significant. To evaluate the extent of difference between patients and the general population sample, the effect size was calculated

**FIGURE 1** Descriptive overview of patients and relatives divided into groups according to when they ended their study participation. **PCS patients**: 3 weeks n = 11, 12 weeks n = 7, 6 months n = 8, 1 year n = 5 and 18 months n = 10. **PCS relatives**: 3 weeks n = 10, 12 weeks n = 8, 6 months n = 8, 1 year n = 5 and 18 months n = 10. **MCS patients**: 3 weeks n = 12, 12 weeks n = 6, 6 months n = 8, 1 year n = 5 and 18 months n = 11. **MCS relatives**: 3 weeks n = 10, 12 weeks n = 8, 6 months n = 8, 1 year n = 5 and 18 months n = 10.
and interpreted with Cohens 0.2–0.5 (small effect), 0.5–0.8 (moderate effect) and >0.8 (large effect). Since the parameter age was not known for the group of relatives, this specific analysis could not be made between relatives and the general population. Analyses were performed in SPSS version 26 (SPSS Statistics; IBM, Armonk, NY, USA).

2.5 | Ethical approval

This study was designed and performed according to the principles of the Declaration of Helsinki. Approval was granted by the Regional Ethical Review Board in Gothenburg, Dnr. 559–12. Licence number for SF-36: QM037698. Before data collection, all participants received oral and written information and gave informed consent. All participants consented to publication. Informed consent and consent to publish was obtained from all participants in this study.

3 | RESULTS

The results presented describe the differences over time in HRQoL and psychological symptoms between patients and their relatives and HRQoL between patients and an age- and gender-matched population.

The results at baseline (pre-surgery) have been described in our previous study but are presented here for the sake of completeness, that is to compare HRQoL and psychological symptoms between patients and their relatives over the entire course of the disease. After patients and relatives were paired, the sample comprised 63 pairs (patients/relatives) pre-surgery, 42 pairs three weeks post-surgery, 32 pairs twelve weeks post-surgery, 25 pairs six months post-surgery, 12 pairs one year post-surgery, 11 pairs eighteen months post-surgery and 6 pairs two years post-surgery. Regarding the longitudinal dropout, 24 patients discontinued participation in connection with their date of death. Due to ethical considerations, we have no data on why the remaining participants chose to discontinue.

3.1 | Health-related quality of life (SF-36)

3.1.1 | SF-36 over time in patients and relatives

To clarify trends in HRQoL over time, the sample was divided into groups and participants were allocated to a specific group according to when study participation ended, that is at three weeks, twelve weeks, six months, one year or eighteen months. The groups of patients who ended participation at twelve weeks, six months and eighteen months post-surgery had a downwards trend (a deterioration) of the SF-36 MCS. In addition, patients generally had a downwards trend for PCS regardless of when they ended their participation in the study. (Figure 1). The MCS was most affected at eighteen months post-surgery. Furthermore, three weeks post-surgery, patients had a noticeably low mean score for SF-36 item RP (Table 2).

For the groups of relatives who ended participation at three weeks, one year and eighteen months post-surgery, a downwards trend (deterioration) of the SF-36 PCS was noted. In addition, MCS in relatives showed a downwards trend in the groups who ended their participation at three weeks, six months and eighteen months post-surgery (Figure 1). Relatives rated all the mental items of SF-36 the lowest (worst) three weeks post-surgery compared to the other time points measured. Furthermore, relatives scored all the mental items of SF-36 highest one year post-surgery (Table 2).

3.1.2 | Psychological symptoms (HADS)

Patients scored probable absence of anxiety symptoms at all time points measured and had the highest mean at eighteen months post-surgery. They did not exceed the threshold for possible presence of depressive symptoms, except at eighteen months post-surgery. Relatives scored possible or probable presence of anxiety symptoms on all but one occasion (one year post-surgery). Their highest risk of symptoms of anxiety appeared to be at two time points: three weeks post-surgery, when 83% of the relative’s scored presence of symptoms of anxiety and eighteen months post-surgery, when this figure increased to 90% (Figure 2, Table 2).

3.2 | Comparisons between patients’ and relatives’ HRQoL and HADS

Prior to surgery and three weeks post-surgery, patients scored worse than relatives on all physical components of SF-36. Furthermore, patients were more physically affected than relatives regarding the SF-36 summary PCS and the items PF and GH at all time points measured (Table 3).

Relatives scored significantly worse than patients on the SF-36 MCS on all occasions, except at eighteen months post-surgery. They also scored lower for the SF-36 item MH than patients at all time points measured, except at six months post-surgery. At three weeks post-surgery, relatives scored worse than patients for several mental components and items of SF-36, MCS (p < .001, RE p = .009 and MH p = .004). Relatives reported a higher risk of symptoms of anxiety and depression compared to patients on many of the occasions measured. Prior to patient surgery, relatives scored worse than patients for both HADa and HADd. Furthermore, relatives scored worse than patients did on HADa at all the time points except eighteen months post-surgery (Table 3).
3.3 Comparison between patients and general population

Comparing patients’ SF-36 PCS and MCS with an age- and gender-matched population, patients scored significantly lower for MCS than the general population at all time points except at one year. PCS was significantly lower at all time points, except before surgery and one year after surgery. The overall effect sizes were moderate (Table 4).
Patients reached a median age of 63.0 (±22.8) at 6 months post-surgery, and 56.1 (±8.8) at 12 weeks post-surgery. Relatives reached a median age of 63.0 (±8.8) at 6 months post-surgery, and 56.1 (±8.8) at 12 weeks post-surgery. Patients in our study, experienced symptoms of anxiety at all time points except one year post-surgery. This indicates that relatives also need targeted support throughout the course of the disease and suggests that it would be worthwhile to screen relatives on several occasions to identify symptoms of anxiety. In addition, our results revealed two time points that proved particularly stressful for the relatives in terms of symptoms of anxiety: at three weeks and at eighteen months post-surgery, when 83% and 90% of the relatives displayed symptoms of anxiety, respectively. It should be noted; however, that the sample was small (n = 11) at eighteen months post-surgery.

The few previous studies that have, to date, longitudinally monitored relatives of patients with glioblastoma report a high level of distress in the relatives at diagnosis and at follow-up two months later. Furthermore, relatives of patients with a more mixed diagnostic group of high-grade gliomas report the highest distress close to diagnosis, with high levels maintained until six months after patients received chemotherapy. Possible explanations for the pronounced symptoms of anxiety in relatives might be that they are, in a greater extent, reminded of the impending death and the patient's worsening symptoms. Another possible explanation might be that relatives of patients with brain tumours experience increased emotion-based stress due to uncertain outcomes.

**DISCUSSION**

We present evidence suggesting that HRQoL and psychological symptoms in patients with glioblastoma and their relatives are affected throughout the disease trajectory. In patients the physical HRQoL was impaired, whilst relatives in our study scored impaired mental HRQoL and psychological symptoms on almost all occasions. Furthermore, patients scored worse physical and mental HRQoL than an age- and gender-matched reference population. Patients and relatives estimated low HRQoL preoperatively and throughout the disease trajectory up until two years post-surgery. These results highlight the importance of support both before surgery and during the entire disease process.

Other studies have shown that increased support can reduce the anxiety of relatives of patients with other cancer types and that supportive conversations have a positive effect on the relatives' distress. Relatives of patients with glioma perceive lack of emotional support, and too much focus on physical care, as negative effect on their psychological symptoms. One possible way to support relatives could be psychoeducation and cognitive Behavioural Therapy, as has been described for patients with high-grade gliomas and their relatives.
In our study, relatives show signs of emotional struggle with a peak at three weeks post-surgery. At this time point, 83% of the relatives rated symptoms of anxiety, compared to 42% of the patients. Furthermore, relatives’ MCS showed a downward trend and relatives rated all mental components of SF-36 lowest at this time point. One way to address their vulnerability could be to screen relatives and offer targeted support to those with high levels of emotional stress.10

Three weeks post-surgery proved to be a particularly challenging period for the relatives, when they appeared to be highly emotionally affected. Previous studies show that patients themselves have a difficult time throughout the course of the disease.7,27,28 In our study, relatives show signs of emotional struggle with a peak at three weeks post-surgery. At this time point, 83% of the relatives rated symptoms of anxiety, compared to 42% of the patients. Furthermore, relatives’ MCS showed a downward trend and relatives rated all mental components of SF-36 lowest at this time point. One way to address their vulnerability could be to screen relatives and offer targeted support to those with high levels of emotional stress.10

To analyse the results, we divided the patients into groups based on when the participants ended their engagement in the study. Examining the dynamic process at the different time points showed a downward trend for patients’ MCS at all measured time points. This result is consistent with a previous study that reported worse levels of HRQoL in patients closer to death.29 The patients’ SF-36 PCS showed a downward spiral, when ending participation in the study, which occurred probably shortly before they died. These data are consistent with the symptom pathway previously described, with increasing physical symptoms closer to death.26,30

### TABLE 3  Comparison between paired patients and relatives at the different time points

|                  | Pre-surgery | 3 weeks     | 12 weeks    |
|------------------|-------------|-------------|-------------|
|                  | n = 63      | n = 42      | n = 32      |
| **Mean difference** |             |             |             |
| (95% CI)         |             |             |             |
| SF-36            |             |             |             |
| PCS              | -14.1 (-17.6, -10.6) | -21.1 (-25.4, -16.8) | -16.9 (-21.1, -12.6) |
| MCS              | 8.0 (3.8, 12.3)  | 14.9 (9.1, 20.0) | 8.4 (2.7, 14.0)  |
| PF               | -20.3 (-28.7, -11.9) | -35.2 (-46.2, -24.1) | -27.7 (-39.0, -16.5) |
| RP               | -50.5 (-63.0, 38.0) | -53.6 (-68.1, -39.0) | -45.3 (-60.7, -29.9) |
| BP               | -10.7 (-19.7, -1.7) | -13.6 (-24.8, -2.5) | -6.2 (-18.4, 6.0)  |
| GH               | -9.7 (-16.1, -3.4)  | -22.1 (-29.7, -14.4) | -24.7 (-33.2, -16.2) |
| VT               | 1.5 (-6.4, 9.5)   | 7.4 (-2.2, 17.0) | 0.3 (-9.8, 10.5)  |
| SF               | -1.2 (-8.8, 6.4)  | -3.6 (-11.6, 4.5) | 1.2 (-9.2, 11.6)  |
| RE               | 2.7 (-12.0, 17.3) | 22.6 (6.5, 38.7) | 4.4 (-15.1, 24.0) |
| MH               | 10.3 (4.2, 16.5)  | 14.1 (5.5, 22.7) | 10.0 (0.3, 19.7)  |
| **HADS**         |             |             |             |
| Anxiety mean (sd)| -2.6 (-4.0, -1.3) | -4.4 (-6.1, -2.8) | -2.3 (-4.3, -0.2) |
| Depression mean (sd) | -1.3 (-2.6, -0.1) | -1.3 (-2.9, 0.2) | -0.3 (-2.4, 1.7) |

*Patients scored worse than relatives.*

*Relatives scored worse than patients.*

Significance of Bold values indicates p < .05.

### TABLE 4  Overview of SF-36 PCS and MCS in patients compared to an age- and gender-matched population at the different time points

|                  | PCS | General population | p-value | Effect size |
|------------------|-----|--------------------|---------|-------------|
|                  | Patients (mean) | (mean) |         |             |
| Pre-surgery (n = 63) | 43.2 | 45.7 | .165 | 0.1 |
| 3 weeks (n = 42) | 34.5 | 45.5 | <.001 | 0.5 |
| 12 weeks (n = 32) | 39.6 | 45.9 | .010 | 0.3 |
| 6 months (n = 25) | 38.6 | 47.1 | .009 | 0.4 |
| 1 year (n = 12) | 43.9 | 46.7 | .239 | 0.3 |
| 18 months (n = 11) | 35.5 | 47.4 | .022 | 0.5 |

|                  | MCS | General population | p-value | Effect size |
|------------------|-----|--------------------|---------|-------------|
|                  | Patients (mean) | (mean) |         |             |
| Pre-surgery (n = 63) | 37.2 | 50.8 | <.001 | 0.5 |
| 3 weeks (n = 42) | 37.2 | 51.0 | <.001 | 0.5 |
| 12 weeks (n = 32) | 39.3 | 46.3 | .02 | 0.3 |
| 6 months (n = 25) | 38.5 | 49.4 | .003 | 0.4 |
| 1 year (n = 12) | 44.3 | 51.1 | .136 | 0.2 |
| 18 months (n = 11) | 35.4 | 51.0 | .013 | 0.6 |

*Age- and gender-matched normative population.*

*Effect size according to Cohen: 0.2-0.5 (small effect), 0.5-0.8 (moderate effect) and >0.8 (large effect).*

Psychological symptoms due to the patient’s suffering, struggle to survive22 and changed personality.22,23,26

Psychological symptoms due to the patient’s suffering, struggle to survive22 and changed personality.22,23,26
When relatives were divided into groups based on the time point at which they ended participation, the SF-36 MCS showed a downward trend at three weeks, 6 months, and 18 months post-surgery. A previous study showed that relatives of patients with high-grade glioma displayed high levels of anxiety up until nine months post-surgery.

Comparisons between the patients and relatives showed that patients generally rated worse than relatives in terms of the physical parts of SF-36 at all measured time points. Due to the symptoms of the disease trajectory, patients are expected to be more physically affected than their relatives. More interesting was the fact that relatives rated worse than patients on the mental parts of SF-36 and for symptoms of anxiety and depression. Relatives also rated worse on HADa and for symptoms of anxiety at most of the measured time points. This result is in agreement with earlier studies where relatives of patients with cancer reported more symptoms of anxiety than the patients themselves\(^\text{10,22}\)—also the case when the patient was close to death.\(^\text{22}\) In addition, another study showed that relatives of patients with high-grade glioma experienced symptoms of anxiety, in contrast with patients who did not report symptoms of anxiety at any time point from radiotherapy until one year post-surgery.\(^\text{31}\)

The HRQoL of patients, presented as PCS and MCS in SF-36, compared with an age- and gender-matched control group, showed that the patients had lower PCS and MCS than the general population at all time points measured. In addition, the patients’ mental HRQoL was affected in connection with oncological treatment, which has been described previously.\(^\text{7,27,28}\) although to date there has been only limited data regarding long-term follow-up. It is alarming that patients with glioblastoma rate HRQoL worse than a matched control group and also have worse HRQoL than patients with other types of malignancies such as breast cancer and lung cancer.\(^\text{7}\) This highlights that patients with glioblastoma and their relatives are in need of specially tailored support throughout the illness trajectory.

## 5 | CONCLUSION

We explored HRQoL and psychological symptoms over time for both patients with glioblastoma and their respective relatives. The main finding was relatives’ emotional difficulties throughout the course of the disease, especially at three weeks post-surgery. Relatives had high levels of anxiety and their mental HRQoL was compromised. They also rated their anxiety and mental component summary worse than patients did. Patients need both physical and emotional support, whilst relatives need mainly emotional support, and it should be noted that targeted support needs to be adapted throughout the illness.

## 6 | STRENGTHS AND LIMITATIONS

The study design, with pairwise comparisons between patients and their respective relatives and encompassing a period as long as two years post-surgery, represents a clear strength. A limitation is the
large dropout over time, which is, however, unavoidable and inherent to the study design. Indeed, the dropout reflects the severity of symptom development in patients with glioblastomas and is a strong argument for investigating the long-term effects of the disease, monitoring HRQoL and psychological symptoms over time. Another limitation is that we only presented descriptive data longitudinally without statistical analysis, again due to the large dropout over time. In addition, a comparison between relatives and an age- and gender-matched control group was not possible, since age as a parameter was missing in the relatives' demographics data.

ACKNOWLEDGEMENTS
The authors would like to thank all patients and their relatives who participated in this study. Furthermore, we would like to thank Dr. Boglarka Fekete for data material, Anneli Johansson, Lena Nilsson, Stina Svensson and Ünzüle Yildiz also Nils-Gunnar Pehrsson for statistical consultation and Nick Guthrie for language review. This study was funded by: Sahlgrenska Academy and Institute of Health and Care Science, University of Gothenburg; Agreement between the Swedish government and the county councils, ALF-agreement, ALFGBG-717021; Health Medical Care Committee at Västra Götaland Regional FoU-support, VGFOUREG-750851; AFA agreement, ALFGBG-717021; Health Medical Care Committee at Health and Care Science, University of Gothenburg; Agreement to the study design. Indeed, the dropout reflects the severity of illness intrusiveness and subjective well-being in patients with glioblastoma. J Neurooncol. 2016;126(1):127-135. doi:10.1007/s00401-016-1545-1

CONFLICT OF INTEREST
The authors have no competing conflicts of interest to declare that are relevant to the content of this study.

AUTHOR CONTRIBUTIONS
Conceptualization and Data curation [P.S, B.R, A.O], Formal analysis [P.S, I.H, A.O], Investigation [P.S, B.R, A.O], Methodology and Validation [P.S, I.H, A.S, B.R, A.O], Visualization [P.S, I.H, A.O], Writing – original draft [P.S, A.O], Writing – review & editing [P.S, I.H, A.S, B.R, A.O]. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT
The datasets analysed during the current study are available from the corresponding author on reasonable request.

ORCID
Pernilla Ståhl https://orcid.org/0000-0002-8293-9905
Ingela Henoch https://orcid.org/0000-0002-1987-5419
Bertil Rydenhag https://orcid.org/0000-0001-8472-5313
Anneli Ozanne https://orcid.org/0000-0003-1737-3359

REFERENCES
1. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020;70(4):299-312. doi:10.3322/caac.21613
2. Ranney PA, Helseth E, Meling TR, Johannesen TB. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro-Oncology. 2012;14(9):1178-1184. doi:10.1093/neuonc/nos153.
3. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708. doi:10.1056/NEJMoa1308573
4. Fekete B, Werlenius K, Örndal C, Rydenhag B. Prognostic factors for glioblastoma patients—a clinical population-based study. Acta Neurol Scand. 2016;133(6):434-441. doi:10.1111/ane.12481
5. Gulati S, Jakola AS, Johannesen TB, Solheim O. Survival and treatment patterns of glioblastoma in the elderly: a population-based study. World Neurosurg. 2012;78(5):518-526. doi:10.1016/j.wneu.2011.12.008
6. Omuro A, Deangelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA, J Am Med Assoc. 2013;310(17):1842-1850. doi:10.1001/jama.2013.280319
7. Edelstein K, Coate L, Massey C, Jewitt N, Mason W, Devins G. Illness intrusiveness and subjective well-being in patients with glioblastoma. J Neurooncol. 2016;126(1):127-135. doi:10.1007/s11060-015-1943-6
8. Sagberg LM, Solheim O, Jakola AS. Quality of survival the 1st year with glioblastoma: a longitudinal study of patient-reported quality of life. JNeurosci. 2016;124(4):989. doi:10.3171/2015.4.JNS15194
9. Ståhl P, Fekete B, Henoch I, et al. Health-related quality of life and emotional well-being in patients with glioblastoma and their relatives. J Neurooncol. 2020;149(2):347-356. doi:10.1007/s11060-020-03614-5
10. Seekatz B, Lukasczik M, Löhr M, et al. Screening for symptom burden and supportive needs of patients with glioblastoma and brain metastases and their caregivers in relation to their use of specialized palliative care. Support Care Cancer. 2017;25(9):2761-2770. doi:10.1007/s00520-017-3687-7
11. Fekete B, Werlenius K, Carén H, et al. The Gothenburg population-based glioblastoma research database: methodological aspects and potential impact. Neurooncol Neurosurg. 2019;2:4-6.
12. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1
13. Louis DN. WHO Classification of Tumours of the Central Nervous System. World Health Organization Classification of Tumours, International Agency for Research on Cancer; 2007.
14. Louis DN, Wiestler OD, Cavenee WK. World Health Organization histological classification of tumours of the central nervous system. IARC; 2016.
15. Bunevicius A. Reliability and validity of the SF-36 Health Survey Questionnaire in patients with brain tumors: a cross-sectional study. Health Qual Life Outcomes. 2017;15(1):92. doi:10.1186/s12955-017-0665-1
16. Sullivan M, Karlsson J, Ware JE. The Swedish SF-36 Health Survey—1. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med. 1995;41(10):1349-1358. doi:10.1016/0277-9536(95)00125-Q
17. Sullivan M. SF-36 hälsokän : svensk manual och tolkningsguide = (Swedish manual and interpretation guide). 2. uppl. ed. (Swedish manual and interpretation guide). Sahlgrenska sjukhuset, Sektionen för vårdforskning; 2002.
18. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale. J Psychiatr Res. 2002;36(2):69-77. doi:10.1016/s0022-3999(01)00296-3
19. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370.
20. Bjelland I, Lie SA, Dahl AA, Mykletun A, Stordal E, Kraemer HC. A dimensional versus a categorical approach to diagnosis: anxiety...
and depression in the HUNT 2 study. Int J Methods Psychiatr Res. 2009;18(2):128-137. doi:10.1002/mpr.284
21. Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed. L. Erlbaum Associates; 1988.
22. Melin-Johansson C, Henoch I, Strang S, Browall M. Living in the presence of death: an integrative literature review of relatives' important existential concerns when caring for a severely ill family member. Open Nurs J. 2012;6:1-12. doi:10.2174/187434601206010001
23. Cavers D, Hacking B, Erridge S, Morris P, Kendall M, Murray S. Adjustment and support needs of glioma patients and their relatives: serial interviews. Psycho-Oncology. 2013;22(6):1299-1305.
24. Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma patients: a randomized controlled trial. J Neurooncol. 2013;111(3):303-311. doi:10.1007/s11060-012-1012-3
25. Halkett GKB, Lobb EA, Shaw T, et al. Distress and psychological morbidity do not reduce over time in carers of patients with high-grade glioma. Support Care Cancer. 2017;25(3):887-893. doi:10.1007/s00520-016-3478-6
26. Cavers D, Hacking B, Erridge SE, Kendall M, Morris PG, Murray SA. Social, psychological and existential well-being in patients with glioma and their caregivers: a qualitative study. CMAJ. 2012;184(7):E373-E382. doi:10.1503/cmaj.111622
27. Rooney AG, Carson A, Grant R. Depression in cerebral glioma patients: a systematic review of observational studies. J Natl Cancer Inst. 2011;103(1):61-76. doi:10.1093/jnci/djq458
28. Bunevicius A, Tamasauskas S, Deltuva V, Tamasauskas A, Radzjinas A, Bunevicius R. Predictors of health-related quality of life in neurosurgical brain tumor patients: focus on patient-centered perspective. Acta Neurochir. 2014;156(2):367-374. doi:10.1007/s00701-013-1930-7
29. Axelsson B, Sjödén P-O. Quality of life of cancer patients and their spouses in palliative home care. Palliat Med. 1998;12(1):29-39. doi:10.1191/026921698676629560
30. Sizoo EM, Dirven L, Reijneveld JC, et al. Measuring health-related quality of life in high-grade glioma patients at the end of life using a proxy-reported retrospective questionnaire. J Neurooncol. 2014;116(2):283-290. doi:10.1007/s11060-013-1289-x
31. Halkett GKB, Lobb EA, Rogers MM, et al. Predictors of distress and poorer quality of life in High Grade Glioma patients. Patient Educ Couns. 2015;98(4):525-532. doi:10.1016/j.pec.2015.01.002
32. Piil K, Laegaard Skovhus S, Tolver A, Jarden M. Neuro-oncological symptoms: a longitudinal quantitative study of family function, perceived support, and caregiver burden. J Fam Nurs. 2022;28(1):43-56. doi:10.1177/10748407211029986

How to cite this article: Ståhl P, Henoch I, Smits A, Rydenhag B, Ozanne A. Quality of life in patients with glioblastoma and their relatives. Acta Neurol Scand. 2022;146:82–91. doi:10.1111/ane.13625